Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Characterization of Angelman Syndrome
This study is currently recruiting participants.
Verified by Office of Rare Diseases (ORD), September 2008
Sponsors and Collaborators: Office of Rare Diseases (ORD)
Rare Diseases Clinical Research Network
Information provided by: Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier: NCT00296764
  Purpose

Angelman Syndrome (AS) is a developmental disorder that is caused by a deficiency of a maternally transmitted gene. It is inherited at birth, and affects movement, speech, and social demeanor. This study will gain a better understanding of the disease progression and clinical features of AS by observing children with AS over an extended period of time.


Condition
Angelman Syndrome

Genetics Home Reference related topics: Angelman syndrome familial paroxysmal nonkinesigenic dyskinesia
U.S. FDA Resources
Study Type: Observational
Study Design: Case-Only, Prospective
Official Title: Angelman's Syndrome Natural History

Further study details as provided by Office of Rare Diseases (ORD):

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Blood and mucusal samples


Estimated Enrollment: 320
Study Start Date: February 2006
Estimated Study Completion Date: September 2008
Estimated Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Detailed Description:

AS is a developmental disorder that affects movement, speech, and social demeanor. The disorder is caused by a deficiency of a maternally transmitted gene and is inherited at birth. Children with AS, however, are often not diagnosed until they are between 3 and 7 years old. Symptoms of AS may include, but are not limited to, functionally severe developmental delay; speech impairments; movement or balance problems; and behavioral uniqueness, including any combination of frequent laughter or smiling, apparent happy demeanor, easily excitable personality, hand flapping movements, and short attention span. There are four molecular variations of AS, but past clinical studies have been inconsistent in highlighting the phenotypic differences between them. This study will gain a better understanding of the disease progression and clinical features of AS by observing children with AS over a period of 5 to 10 years. The study will also attempt to establish genotype-phenotype correlations, which might aid in future clinical care of AS patients.

Participation in this observational study will be limited to current or future patients at one of the four study sites. A clinical evaluation will be performed at baseline, including a general patient history, physical and neurological examinations, a nutritional assessment, neuro-imaging, electroencephalography, laboratory testing, and neurodevelopmental testing. A blood sample or mucosal sample will also be taken at baseline to acquire DNA for potential genetic testing. All assessments except the neuro-imaging, electroencephalography, and blood sampling will be repeated at yearly study visits for a total of 5 years. In addition, participants will be photographed and perhaps videotaped on a yearly basis in order to document clinical phenotypes and any neurologic abnormalities. Participants may be followed-up for a total of 10 years.

  Eligibility

Ages Eligible for Study:   up to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Current or future patient at one of the following institutions: Baylor College of Medicine; Children's Hospital San Diego; Boston Children's Hospital; or Greenwood Genetic Center

Criteria

Inclusion Criteria:

  • Current or future patient at one of the following institutions: Baylor College of Medicine; Children's Hospital San Diego; Boston Children's Hospital; or Greenwood Genetic Center
  • Meets all major diagnostic criteria for Angelman Syndrome and 3 of the 6 minor criteria:

Major Criteria:

  • Functionally severe developmental delay
  • Speech impairment; none or minimal words used
  • Movement or balance disorder
  • Behavioral uniqueness, frequent laughs/smiling, excitable personality, hand flapping, short attention span

Minor Criteria:

  • Deceleration in head circumference growth (post-natal)
  • Seizures (myoclonic, absence, drop, tonic-clonic)
  • Abnormal EEG (with patterns suggestive of AS, or hypsarrhythmia)
  • Sleep disturbance
  • Attraction to or fascination with water
  • Drooling

Exclusion Criteria:

  • Does not meet diagnostic criteria for Angelman Syndrome
  • Other medical or genetic disorders (except autism)
  • Born extremely prematurely
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00296764

Contacts
Contact: Carlos A. Bacino, MD 832-822-4292 cbacino@bcm.tmc.edu

Locations
United States, California
Children's Hospital and Health Center Recruiting
San Diego, California, United States, 92123
Contact: Lynne M. Bird, MD     858-966-5840     lbird@rchsd.org    
Principal Investigator: Lynne Bird, MD            
United States, Massachusetts
Children's Hospital Boston Recruiting
Boston, Massachusetts, United States, 02115
Contact: Wen-Hann Tan, BMBS         Wen-Hann.Tan@childrens.harvard.edu    
Principal Investigator: Wen-Hann Tan, BMBS            
United States, South Carolina
Greenwood Genetic Center Recruiting
Greenwood, South Carolina, United States, 29646
Contact: Steven A. Skinner, MD     864-941-8164     sas@ggc.org    
Principal Investigator: Steven A. Skinner, MD            
United States, Tennessee
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37232-4315
Contact: Terry Jo Bichell     615-322-8093     terry.jo.bichell@vanderbilt.edu    
Principal Investigator: Marshall L. Summar, MD            
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Beverly Feldman, RN     832-822-4280     bfeldman@bcm.tmc.edu    
Principal Investigator: Carlos A. Bacino, MD            
Sponsors and Collaborators
Rare Diseases Clinical Research Network
Investigators
Principal Investigator: Carlos A. Bacino, MD Baylor College of Medicine, Department of Molecular and Human Genetics
Principal Investigator: Lynne Bird, MD Children's Hospital San Diego, Department of Pediatrics
Principal Investigator: Steven A. Skinner, MD Greenwood Genetic Center
Principal Investigator: Wen-Hann Tan, BMBS Children's Hospital Boston
  More Information

Publications:
Responsible Party: Baylor College of Medicine ( Carlos A. Bacino )
Study ID Numbers: RDCRN 5203, U54 RR019478, ARP 5203
Study First Received: February 24, 2006
Last Updated: September 2, 2008
ClinicalTrials.gov Identifier: NCT00296764  
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
Happy Puppet Syndrome
Developmental Disorders

Study placed in the following topic categories:
Chromosomal abnormalities
Developmental Disabilities
Angelman syndrome
Genetic Diseases, Inborn
Movement Disorders
Chromosome Disorders
Abnormalities, Multiple
Central Nervous System Diseases
Angelman Syndrome
Congenital Abnormalities

Additional relevant MeSH terms:
Pathologic Processes
Disease
Syndrome
Nervous System Diseases

ClinicalTrials.gov processed this record on January 15, 2009